Eli Lilly and Company is reportedly close to acquiring Kelonia Therapeutics in a deal valued at more than $2 billion, according to a report that cites people familiar with the matter.
The agreement, which could be finalized as early as Monday, may also include additional payments if Kelonia meets certain development milestones.
